Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers

BACKGROUND: Cladribine tablets 3.5 mg/kg cumulative over 2 years (CT3.5) had significant clinical/imaging effects in patients with clinically isolated syndrome (CIS; ORACLE-MS) or relapsing-remitting MS (RRMS; CLARITY and CLARITY Extension). This analysis compared the effect of cladribine tablets on...

Descripción completa

Detalles Bibliográficos
Autores principales: Stuve, Olaf, Soelberg Soerensen, Per, Leist, Thomas, Giovannoni, Gavin, Hyvert, Yann, Damian, Doris, Dangond, Fernando, Boschert, Ursula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582297/
https://www.ncbi.nlm.nih.gov/pubmed/31244898
http://dx.doi.org/10.1177/1756286419854986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582297/
https://www.ncbi.nlm.nih.gov/pubmed/31244898
http://dx.doi.org/10.1177/1756286419854986

Ejemplares similares